1. Nā ʻano: ʻO ka pauka keʻokeʻo a kokoke i ke keʻokeʻo, hygroscopic nui.
2. Puna: Puka ʻōpū mucosa.
3. Ke Kaʻina Hana: Hoʻopuka ʻia ka sodium Heparin mai ka mucosa o ka ʻōpū puaʻa olakino.
4. Nā hōʻailona a me ka hoʻohana ʻana: Hoʻohana nui ʻia kēia huahana no ka pale ʻana i ka maʻi thromboembolic, ʻoi aku ka maikaʻi no ka pono o ka anticoagulant wikiwiki, e like me: 1. Acute a maʻi venous thrombosis a ʻaʻohe hoʻololi koʻikoʻi kahe koko o ka pulmonary embolism (PE). Heparin Hiki iā ia ke ho'ōki i ka hoʻonui ʻana o ka embolus e hoʻolōʻihi i ka manawa no ka thrombolysis o ke kino.2. Kāohi a mālama ʻana i ka fibrillation Atrial me ka embolism.3. Hoʻomaʻamaʻa ʻana i ka coagulation intravascular diffuse mua (DIC).4. Ka pale ʻana a me ka mālama ʻana i ka thrombosis arterial peripheral a i ʻole myocardial infarction.5. ʻO nā mea ʻē aʻe in vitro anticoagulation: e like me ka ʻoki cardiovascular, in vitro circulation, hemodialysis, angiography, hiki ke hoʻohana ʻia no ka transfusion a i ʻole ka hoʻomākaukau ʻana i ke koko, i kēia manawa nā hōʻailona nui o ka noi heparin he thrombosis vein hohonu (DVT), PE a me ka thrombosis i nā maʻi pilikia nui.
· Ua hala i ka GMP Kina
· 27 makahiki o ka moʻolelo R&D biological enzyme
· Hiki ke ʻimi ʻia nā mea maka
· E hoʻokō me ka USP、EPa me ka mea kūʻai maʻamau
· Hoʻokuʻu aku i 30 mau ʻāina a me nā ʻāina
· Loaʻa ka mana o ka hoʻokele ʻōnaehana maikaʻi e like me US FDA, Japan PMDA, South Korea MFDS, etc.
Nā mea ho'āʻo | Hōʻikeʻike Hui | ||
EP | USP | ||
Nā huaʻōlelo | ʻO ka pauka keʻokeʻo a aneane keʻokeʻo paha, hygroscopic nui | ||
ʻIkepili | Thrombotest: Kūlike | ʻIkepili Chromatographic: Kūlike | |
1H NMR Spectrum: Kūlike | 1H NMR Spectrum: Kūlike | ||
Kromatography Liquid: Kūlike | Kaumaha-awelika molecular kaumaha: 15000~19000 | ||
Sodium: Kūlike | Sodium: Kūlike | ||
Anati-factor Xa i anti-factor IIa ratio:0.9~1.1 | Anati-factor Xa i anti-factor IIa ratio:0.9~1.1 | ||
Nā hoʻāʻo | Ka malamalama a me ke kala | Mākaʻikaʻi: Akaka, kala: e 5 a ʻoi aku paha | ———— |
Nitrogen | 1.5~2.5%(mea maloo) | 1.3~2.5%(mea maloo) | |
Nucleotidic haumia | A260≤ 0.15(4mg/ml) | ≤ 0.1(w/w) | |
Nā mea pili | Kūlike | ———— | |
Ka palena o ka galactosamine i ka huina hexosamine | ———— | ≤ 1.0% | |
Oversulfated chondroitin sulfate | ———— | Kūlike | |
pH | 5.5~8.0(1%) | 5.5~7.5(1%) | |
Pohō ma ka maloʻo | ≤ 8.0%(60 ℃ Maloo i loko o ka Mūmā, 3h) | ≤ 5.0%(60 ℃ Maloo i loko o ka Mūmā, 3h) | |
Ke koena ma ka ʻā | ———— | 28.0%~41.0% | |
Endotoxin bacteria | ≤ 0.01 IU/Hui Hui Pū ʻIa o Heparin | ≤ 0.03 USP U/Wāhi Mokupuni o Heparin | |
Metala kaumaha | ≤ 30ppm | ≤ 30ppm | |
Sodium | 10.5~13.5%(mea maloo) | ———— | |
Pākīpika | ≤ 0.5%(mea maloo) | ≤ 0.1%(ratio kaumaha) | |
Ka hana | ≥ 180 IU/mg(mea maloo) | ≥ 180 USP U/mg(mea maloo) | |
ʻO nā meaʻeleʻele microbial | TAMC | ≤ 1000cfu/g | ≤ 1000cfu/g |
TYMC | ≤ 100cfu/g | ≤ 100cfu/g | |
E.coli | Kūlike | Kūlike | |
ʻO Staphylococcus aureus | Kūlike | Kūlike | |
Salmonella | Kūlike | Kūlike |